Sirolimus Conversion for Renal Dysfunction in Liver Transplant Recipients: The Devil Really Is in the Details…

Authors

  • G. J. McKenna,

    Corresponding author
    1. Department of Surgery, Baylor University Medical Center, Dallas, TX
    2. Annette C and Harold C Simmons Transplant Institute, Dallas, TX
    Search for more papers by this author
  • J. F. Trotter

    1. Annette C and Harold C Simmons Transplant Institute, Dallas, TX
    2. Department of Medicine, Baylor University Medical Center, Dallas, TX
    Search for more papers by this author

Greg J. McKenna, greg.mckenna@baylorhealth.edu

Abstract

The authors revisit the current FDA warnings applied to the use of sirolimus in liver transplantation, indicating that they are best considered in the context of comprehensive clinical trial data. See article by Abdelmalek et al on page 694.

Ancillary